ClinicalTrials.gg
TerminatedNCT03300362INVICTUSUpdated Nov 23, 2018

Improved Novel VaccIne CombinaTion InflUenza Study

A Phase 2 interventional study of Seasonal influenza vaccine and MVA-NP+M1 in Influenza, sponsored by Barinthus Biotherapeutics. Terminated at 5 sites in United Kingdom. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-23.

Sponsored by Barinthus Biotherapeutics · Phase 2, Interventional, and Prevention

How we know

Why this study was terminated
Change to recommended season flu vaccine in UK

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
862
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 151 studies in Influenza, Human with a site in United Kingdom — 8 open to participants now, 13 under way, 4 of them phase 3. Influenza, Human · United Kingdom.

Enrollment
23rd of 123
862 · median 129
Started
2017
with 5 others
Phase 2
38 of 151
2 open now
Registered
105th of 151
by date

Among the 151 studies in Influenza, Human with a site in United Kingdom, this one is the 23rd largest by enrollment of the 123 interventional ones that give a count, is one of 6 that started in 2017, is one of 38 in phase 2, and was the 105th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

8 of the 151 studies in Influenza, Human with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Influenza, Human with a site in United Kingdom, or all of them as a file.
02

Study summary

A Phase IIb randomised, participant-blinded, placebo-controlled, multi-centre phase IIb efficacy study in 2030 volunteers aged 65 and over. The study will assess the safety and efficacy of the co-administration of a viral vectored vaccine, MVA- NP+M1, and the annual recommended licensed inactivated influenza vaccine (IIV). Within the main cohort 100 participants will be recruited to an immunology sub-cohort.

Read the detailed description

The efficacy of current seasonal influenza vaccines is limited in the face of antigenic mismatch between circulating viral strains and those in the given vaccine. Additionally vaccination in older adults, a major target group for vaccination, prevents laboratory-confirmed influenza in only 30-40% compared to 70-90% in young adults. The hypothesis in this Phase IIb efficacy study is that a new vaccine MVA-NP+M1 with licensed inactivated influenza vaccine (IIV) in the older age group will be able to induce immune responses that protect individuals against influenza illness, severity of symptoms and reduce viral shedding, thereby increasing the protection conferred by seasonal influenza vaccine alone. A total of 2030 participants who are 65 years of age or over and eligible for annual seasonal influenza vaccination and provide informed consent will be recruited to the study. Potential volunteers will be mailed an invitation to take part by their GPs or recruited by local advertisements. Participants will be randomised to receive either MVA- NP+M1 with licensed IIV or saline placebo with licensed IIV. In the first 28 days after vaccination, participants will record adverse events using an electronic or paper diary. The participants will be contacted by telephone 1 day and 7 days post-vaccination to enquire about any serious adverse events and support follow up. During influenza season participants will record weekly whether or not they have had an influenza like illness (ILI). For every ILI episode experienced, the participants will record the severity of their symptoms daily. Among the participants, a total of 100 volunteers (50 in each group) will be recruited into an immunology sub-cohort. They will have blood samples collected on the day of vaccination, 1 week, 3 weeks and 26 weeks post-vaccination for monitoring of laboratory adverse events and immunogenicity purposes.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteer is willing and has capacity to provide written for participation in the trial (in the Investigator's opinion).
  • Male or female adults, aged 65 years and above
  • Able and willing (in the Investigator's opinion) to comply with all study requirements
  • Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner
  • Eligible to receive seasonal influenza vaccine

Exclusion criteria

Exclusion Criteria:

  • Any history of anaphylaxis in reaction to vaccination or history of allergic reactions likely to be exacerbated by any component of the vaccine (e.g. egg allergy)
  • Ongoing terminal illness with a estimated to be approximately \<6 months.
  • Continuous use of oral anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban)
  • Any other significant disease, disorder or finding (including blood test results), which, in the opinion of the Investigators, would either put the volunteer at risk because of participation in the study, or may influence the result of the study
  • Participation in another clinical trial of an medicinal product in the 30 days preceding enrolment, or planned use during the study period
  • Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data
  • Receipt of annual seasonal influenza vaccine prior to enrolment (for the same influenza season volunteers are recruited in)
  • Not willing to comply with study procedures
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
862 participants (actual)

Study arms

  • Experimental
    Seasonal influenza & MVA-NP+M1

    Two vaccinations will be administered: Seasonal influenza vaccine \& MVA-NP+M1

    Drug: Seasonal influenza vaccine · Drug: MVA-NP+M1

  • Placebo comparator
    Seasonal influenza & saline placebo

    Two vaccinations will be administered: Seasonal influenza vaccine \& sodium chloride

    Drug: Seasonal influenza vaccine · Drug: Sodium chloride

Interventions

  • DrugSeasonal influenza vaccine

    Seasonal influenza vaccine

    Also known as: Quadrivalent Influenza Vaccine

  • DrugMVA-NP+M1

    Drug page: MVA-NP+M1Studies of MVA-NP+M1MVA-NP+M1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Trial vaccine

  • DrugSodium chloride

    Saline placebo

06

What researchers measure

Primary outcomes

  1. Number of days with moderate or severe influenza-like symptoms

    Throughout the influenza season, self-reported symptoms recorded using electronic or paper diaries

    Time frame: 6-7 months

Secondary outcomes

  1. Incidence of influenza-like-illness

    Throughout the influenza season, self-reported symptoms recorded using electronic or paper diaries

    Time frame: 6-7 months

  2. Severity of influenza-like symptoms

    Throughout the influenza season, self-reported symptoms recorded using electronic or paper diaries

    Time frame: 6-7 months

  3. Duration of influenza-like-illnes

    Throughout the influenza season, self-reported symptoms recorded using electronic or paper diaries

    Time frame: 6-7 months

  4. Occurrence of GP consultations from respiratory illness

    Throughout the influenza season - self-reported and Medical Records

    Time frame: 6-7 months

  5. Occurrence of hospitalisations and deaths due to respiratory illness

    Throughout the influenza season - self-reported and Medical Records

    Time frame: 6-7 months

  6. Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination

    Self-reported symptoms recorded using electronic or paper diaries

    Time frame: Day 0-7

  7. Occurrence of serious adverse events during the whole study duration

    Telephone calls on Day 1-3, day 7-9 and every 3-4 weeks throughout volunteers' participation in the trial

    Time frame: 6-7 months

  8. Occurrence of unsolicited adverse events for 28 days following vaccination

    Self-reported symptoms recorded using electronic or paper diaries

    Time frame: Day 0-28

  9. Frequency of influenza-specific T-cells measured by IFNg ELISpot

    To assess the immunogenicity of MVA-NP+M1 in combination with the recommended licensed inactivated influenza vaccine in adults aged 65 years and above

    Time frame: 6-7 months

  10. Geometric mean titre of influenza-specific neutralising antibodies

    To assess the immunogenicity of MVA-NP+M1 in combination with the recommended licensed inactivated influenza vaccine in adults aged 65 years and above

    Time frame: 6-7 months

  11. Breadth of influenza-specific T-cells and antibodies

    To assess the immunogenicity of MVA-NP+M1 in combination with the recommended licensed inactivated influenza vaccine in adults aged 65 years and above

    Time frame: 6-7 months

Other outcomes

  1. Estimated frequency of influenza infection using historical data on the proportion of ILIs that is caused by influenza virus infection.

    To explore novel clinical endpoints for future Phase III efficacy trials of influenza vaccines

    Time frame: 6-7 months

07

Study locations

5 sites
  • The Boathouse Surgery
    Pangbourne, Berkshire RG8 7DF, United Kingdom
  • Wokingham Medical Centre
    Wokingham, Berkshire RG40 1XS, United Kingdom
  • Bicester Health Centre
    Bicester, Oxfordshire OX26 6AT, United Kingdom
  • Centre for Clinical Vaccinology and Tropical Medicine (CCVTM
    Oxford, Oxfordshire OX3 7LJ, United Kingdom
  • Windrush Health Centre
    Witney, Oxfordshire OX28 6JS, United Kingdom
08

References and documents

Publications

  • Swayze H, Allen J, Folegatti P, Yu LM, Gilbert S, Hill A, Ellis C, Butler CC. A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above (INVICTUS): a study protocol. F1000Res. 2019 May 23;8:719. doi: 10.12688/f1000research.19090.1. eCollection 2019. PubMed 32089822 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Oct 2018, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2017
First posted
Oct 3, 2017
StartActual
Oct 13, 2017
Primary completionActual
Oct 31, 2018
CompletionActual
Oct 31, 2018
Last update
Nov 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03300362
Lead sponsor
Barinthus Biotherapeutics
Responsible party
Sponsor
First posted
Oct 3, 2017
Start date
Oct 13, 2017
Primary completion
Oct 31, 2018
Completion
Oct 31, 2018
Last update
Nov 23, 2018

Study contacts

Christopher Butler
principal investigator · University of Sussex

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MVA-NP+M1

Start the discussion